Pan Cancer T

Foundation date



#Biotechnology - Therapeutics


Pan Cancer T is a biotech spin-out that builds further on 20 years of pioneering in adoptive cell therapy developed in the laboratories of Erasmus MC. We intend to lead the fight against solid cancers through T cell receptor (TCR) gene engineered T-cell therapy. Especially, those solid cancers for which there are limited treatment options and a poor prognosis.

Upcoming events

Latest news

  • HERAN Partners co-leads the GBP 6,5m financing round of Hypervision Surgical to support the further development and commercial roll-out of their Hyperspectral Imaging platform

    Tuesday June 6th 2023

  • ANeuroTech receives IND approval from the FDA for pivotal Phase IIIB trial of adjunctive anti-depression drug, ANT-01

    Monday June 5th 2023

  • Biotalys continues to demonstrate strength of first biocontrol in latest global field trials

    Friday June 2nd 2023